ZHIGANG-WANG

  • KU Leuven

Author Archive | ZHIGANG-WANG

Modeling of The Relationship Between Ustekinumab Exposure, Fecal Calprotectin and Endoscopic Outcomes in Patients with Crohn’s Disease

Background: Ustekinumab is approved for the treatment of patients with moderate-to-severe Crohn’s disease (CD) and ulcerative colitis. In the UNITI endoscopy sub-study, only 17.4% of patients on ustekinumab achieved endoscopic response and 10.9% of patients achieved endoscopic remission at week 44 (w44).1 Aims: We aimed to investigate if improved endoscopic outcomes could be achieved through dose optimization […]

Continue Reading